×
Sunday, April 19, 2026
Get News Alerts

Novartis Dodges Whistleblower Lawsuit Regarding Multiple Sclerosis Drug Kickback Claims - Novartis (NYSE:NVS) - Benzinga

by Vandana Singh
Wed, Sep 14, 2022 14:05 ET
in Employment News, Press Release

  • U.S. District Judge Kimba Wood dismissed the whistleblower lawsuit, arguing that former Novartis sales representative Steven Camburn did not provide enough detail to support his claims.
  • Camburn's lawyer says he and his client plan to appeal the decision, adding that they're confident the ruling will be reversed, Reuters reports.
  • Gilenya was the company's third-best-selling drug in 2021, bringing in $2.8 billion worldwide out of $51.6 billion in total sales.
  • Camburn sued Novartis in 2013 under the False Claims Act, claiming that Novartis paid doctors up to $3,500 to participate as speakers in purportedly educational speaker events to induce them to prescribe and promote Gilenya.
  • Novartis, in 2020, agreed to pay $729 million to settle similar whistleblower claims related to its speaker program and its diabetes and cardiovascular drugs.
  • Price Action: NVS shares are down 1.55% at $80.68 on the last check Wednesday.


Read Full Story: https://www.benzinga.com/general/biotech/22/09/28868709/novartis-dodges-whist...


False Claims